Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti–tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries

Journal of the American Academy of Dermatology

Volumn 76, Issue 2, 2017, Pages 299-308.e16

  García Doval, Ignacio ^a,b   Cohen, Arnon D ^c,d   Feldhamer, Ilan ^c,d   Cazzaniga, Simone ^e   Naldi, Luigi ^e   Addis, Antonio ^f   Carretero, Gregorio ^g   Ferrándiz, Carlos ^h   Stern, Robert S ⁱ  

^a Research Unit   (Spain)

^b UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^c CLALIT HEALTH SERVICES   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f DEPARTMENT OF EPIDEMIOLOGY   (Italy)

^g HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

Author keywords

anti inflammatory agents; anti tumor necrosis factor; biological agents; immunosuppressive agents; psoriasis drug therapy; safety

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; USTEKINUMAB; TUMOR NECROSIS FACTOR;

ARTICLE; BACTERIAL SKIN DISEASE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMPARATIVE STUDY; CRYPTOCOCCOSIS; FOLLOW UP; GRANULOMATOSIS; HOSPITALIZATION; HUMAN; INFECTION RISK; META ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RISK FACTOR; TUBERCULOSIS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; GRANULOMA; INFECTION; MICROBIOLOGY; REGISTER; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SKIN DISEASES, BACTERIAL;

GRANULOMA; HUMANS; INFECTION; PROSPECTIVE STUDIES; PSORIASIS; REGISTRIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SKIN DISEASES, BACTERIAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84999808836     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.07.039     Document Type: Article

References (26)

1. International Conference on Harmonization. International Conference on Harmonization E2A guideline 1994. Available from: URL: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf. Accessed July 1, 2016.
2. Yiu, Z.Z., Exton, L.S., Jabbar-Lopez, Z., et al. Risk of serious infections in patients with psoriasis on biologic therapies: a systematic review and meta-analysis. J Invest Dermatol 136 (2016), 1584–1591.
3. Dixon, W.G., Watson, K., Lunt, M., et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54 (2006), 2368–2376.
4. Jourabchi, N., Adelzadeh, L., Wu, J.J., The risk of deep fungal infections during biologic therapy for psoriasis. J Eur Acad Dermatol Venereol 28 (2014), 1277–1285.
5. Gomez-Reino, J.J., Carmona, L., Valverde, V.R., Mola, E.M., Montero, M.D., BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48 (2003), 2122–2127.
6. Souto, A., Maneiro, J.R., Salgado, E., Carmona, L., Gomez-Reino, J.J., Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology 53 (2014), 1872–1885.
7. Kalb, R.E., Fiorentino, D.F., Lebwohl, M.G., et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol 151 (2015), 961–969.
8. Kimball, A.B., Rothman, K.J., Kricorian, G., et al. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. J Am Acad Dermatol 72 (2015), 115–122.
9. Menter, A., Thaci, D., Papp, K.A., et al. Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. J Am Acad Dermatol 73 (2015), 410–419.e6.
10. Rivera, R., Garcia-Doval, I., Carretero, G., et al. BIOBADADERM, the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology: first report. [in Spanish] Actas Dermosifiliogr 102 (2011), 132–141.
11. Carretero, G., Ferrandiz, C., Dauden, E., et al. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry. J Eur Acad Dermatol Venereol 29 (2015), 156–163.
12. Cohen, A.D., Dreiher, J., Shapiro, Y., et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 22 (2008), 585–589.
13. Cohen, A.D., Weitzman, D., Dreiher, J., Psoriasis and hypertension: a case-control study. Acta Derm Venereol 90 (2010), 23–26.
14. Gisondi, P., Cazzaniga, S., Chimenti, S., et al. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. J Eur Acad Dermatol Venereol 27 (2013), e30–e41.
15. Naldi, L., Addis, A., Chimenti, S., et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology 217 (2008), 365–373.
16. Gisondi, P., Cazzaniga, S., Chimenti, S., et al. Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare registry. Br J Dermatol 172 (2015), 1613–1620.
17. Sanchez-Moya, A.I., Garcia-Doval, I., Carretero, G., et al., BIOBADADERM registry. Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. J Eur Acad Dermatol Venereol 27 (2013), 1366–1374.
18. Huntley, A.L., Johnson, R., Purdy, S., Valderas, J.M., Salisbury, C., Measures of multimorbidity and morbidity burden for use in primary care and community settings: a systematic review and guide. Ann Fam Med 10 (2012), 134–141.
19. Borenstein, M., Simpson's paradox. Introduction to meta-analysis. 2009, John Wiley and Sons, Chichester (United Kingdom), 303–309.
20. Garcia-Doval, I., Carretero, G., Vanaclocha, F., et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol 148 (2012), 463–470.
21. Ormerod, A.D., Augustin, M., Baker, C., et al. Challenges for synthesizing data in a network of registries for systemic psoriasis therapies. Dermatology 224 (2012), 236–243.
22. Garcia-Doval, I., Rustenbach, S.J., Stern, R., et al. Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries. Br J Dermatol 169 (2013), 710–714.
23. Ramiro, S., Gaujoux-Viala, C., Nam, J.L., et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73 (2014), 529–535.
24. Garcia-Doval I, Hernandez MV, Vanaclocha F, et al. Should TNF-antagonists safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts. Br J Dermatol. doi: http://dx.doi.org/10.1111/bjd.14776. Published online October 3, 2016.
25. Hsu, D.Y., Gordon, K., Silverberg, J.I., Serious infections in hospitalized patients with psoriasis in the United States. J Am Acad Dermatol 75 (2016), 287–296.
26. Wakkee, M., de Vries, E., van den Haak, P., Nijsten, T., Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort. J Am Acad Dermatol 65 (2011), 1135–1144.